We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Correvio

News List

Correvio receives FDA complete response letter for anti-arrhythmic drug Brinavess firstwordpharma
December 25, 2019
Correvio Pharma announced Tuesday that the FDA issued a complete response letter regarding its filing seeking approval of Brinavess (vernakalant) for the rapid conversion of recent-onset atrial fibrillation in adults, sending shares down as much as 12%.
FDA Accepts Correvio's Resubmitted NDA for Brinavess americanpharmaceuticalreview
July 29, 2019
Correvio Pharma announced the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for Brinavess™ (vernakalant hydrochloride, IV), an antiarrhythmic drug for ...
Correvio Resubmits Brinavess (vernakalant) New Drug Application to U.S. FDA for the Treatment of Patients with Recent Onset Atrial Fibrillation drugs
June 26, 2019
Correvio Resubmits Brinavess (vernakalant) New Drug Application to U.S. FDA for the Treatment of Patients with Recent Onset Atrial Fibrillation.